| Joni Clark, | |
|
14 S Main St Ste 1e, Aberdeen, SD 57401-4189 | |
| (605) 225-1010 | |
| (605) 725-8055 |
| Full Name | Joni Clark |
|---|---|
| Gender | Female |
| Speciality | Counselor - Professional |
| Location | 14 S Main St Ste 1e, Aberdeen, South Dakota |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1851006407 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 101Y00000X | Counselor | (* (Not Available)) | Secondary |
| 101YP2500X | Counselor - Professional | LPC20806 (South Dakota) | Primary |
| Entity Name | Northeastern Mental Health Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801964952 PECOS PAC ID: 0446155816 Enrollment ID: O20031201000100 |
News Archive
Findings published in Diabetes Care from a 12-week, Phase IIb dose-ranging study showed that dapagliflozin, a novel, selective, sodium glucose co-transporter2 (SGLT2) inhibitor, produced clinically meaningful reductions across all key glycemic measures studied [glycosylated hemoglobin level (HbA1c), fasting plasma glucose (FPG), and postprandial plasma glucose (PPG)] in treatment-naive type 2 diabetes patients, compared to placebo.
Myrexis, Inc., a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today announced it will present a poster at the 74th Annual Scientific Meeting of the American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP), to be held November 7-11, 2010 in Atlanta, Georgia.
Vertex Pharmaceuticals Incorporated today announced new data from its Phase 3 studies of people with genotype 1 chronic hepatitis C who have not been treated previously. In these studies, the majority of people achieved superior sustained viral response (SVR or viral cure) rates with a telaprevir-based combination regimen, compared to current therapies, regardless of race/ethnicity or stage of liver fibrosis (factors known to limit response to current hepatitis C treatments).
The Food and Drug Administration has approved the first focused ultrasound device to treat essential tremor, the most common movement disorder, in patients who do not respond to medication.
Since approximately seventy percent of the neural connections in the brain are involved with vision and visual processing, how likely is it that a concussion will cause visual disturbances? Can potential problems be avoided or treated with vision therapy?
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Joni Clark, 14 S Main St Ste 1e, Aberdeen, SD 57401-4189 Ph: (605) 225-1010 | Joni Clark, 14 S Main St Ste 1e, Aberdeen, SD 57401-4189 Ph: (605) 225-1010 |
News Archive
Findings published in Diabetes Care from a 12-week, Phase IIb dose-ranging study showed that dapagliflozin, a novel, selective, sodium glucose co-transporter2 (SGLT2) inhibitor, produced clinically meaningful reductions across all key glycemic measures studied [glycosylated hemoglobin level (HbA1c), fasting plasma glucose (FPG), and postprandial plasma glucose (PPG)] in treatment-naive type 2 diabetes patients, compared to placebo.
Myrexis, Inc., a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today announced it will present a poster at the 74th Annual Scientific Meeting of the American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP), to be held November 7-11, 2010 in Atlanta, Georgia.
Vertex Pharmaceuticals Incorporated today announced new data from its Phase 3 studies of people with genotype 1 chronic hepatitis C who have not been treated previously. In these studies, the majority of people achieved superior sustained viral response (SVR or viral cure) rates with a telaprevir-based combination regimen, compared to current therapies, regardless of race/ethnicity or stage of liver fibrosis (factors known to limit response to current hepatitis C treatments).
The Food and Drug Administration has approved the first focused ultrasound device to treat essential tremor, the most common movement disorder, in patients who do not respond to medication.
Since approximately seventy percent of the neural connections in the brain are involved with vision and visual processing, how likely is it that a concussion will cause visual disturbances? Can potential problems be avoided or treated with vision therapy?
› Verified 3 days ago
Taylor A Petersen, Counselor Medicare: Not Enrolled in Medicare Practice Location: 14 S Main St Ste 1e, Aberdeen, SD 57401 Phone: 605-225-1010 Fax: 605-725-8055 | |
Madalyn Pederson, Counselor Medicare: Not Enrolled in Medicare Practice Location: 14 S Main St Ste 1e, Aberdeen, SD 57401 Phone: 605-225-1010 | |
Sheila Snover, Counselor Medicare: Not Enrolled in Medicare Practice Location: 628 Circle Dr, Aberdeen, SD 57401 Phone: 605-225-1010 Fax: 605-725-8057 | |
Amy L Hauge, LPC-MH, QMHP Counselor Medicare: Not Enrolled in Medicare Practice Location: 125 Railroad Ave Se Ste 1, Aberdeen, SD 57401 Phone: 605-725-5505 | |
Nancy Yada, Counselor Medicare: Not Enrolled in Medicare Practice Location: 14 S Main St, Suite 1e, Aberdeen, SD 57401 Phone: 605-225-1010 Fax: 605-225-1017 | |
Reagan M Flamboe, Counselor Medicare: Medicare Enrolled Practice Location: 14 S Main St, Suite 1e, Aberdeen, SD 57401 Phone: 605-225-1010 Fax: 605-225-1017 | |
Megan Hulke, Counselor Medicare: Not Enrolled in Medicare Practice Location: 14 S Main St Ste 1e, Aberdeen, SD 57401 Phone: 605-725-4956 Fax: 605-725-8055 |